ciprofibrate and tyloxapol

ciprofibrate has been researched along with tyloxapol in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Borensztajn, J; Davidson, NO; Fu, T; Mukhopadhyay, D1

Other Studies

1 other study(ies) available for ciprofibrate and tyloxapol

ArticleYear
The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
    The Journal of biological chemistry, 2004, Jul-02, Volume: 279, Issue:27

    Topics: Animals; Aorta; Apolipoproteins B; Arteriosclerosis; Blotting, Western; Cholesterol; Clofibric Acid; Cytoplasm; Female; Fibric Acids; Intestinal Mucosa; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peroxisome Proliferators; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; RNA; RNA Editing; RNA, Messenger; Time Factors; Transcription Factors; Triglycerides

2004